The diagnostics company has implemented the
SOPHiA DDM™ Platform to enhance its solid tumor
testing
BOSTON and ROLLE,
Switzerland, July 4, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
healthcare technology company and a global leader in data-driven
medicine, today announced that Dhiti Omics Technologies, a
precision molecular diagnostics service provider in India, is live on the SOPHiA
DDM™ Platform. The company will use SOPHiA GENETICS'
technology to enhance its solid tumor
testing capabilities.
Dhiti Omics specializes in molecular diagnostic and genetic
testing. By implementing SOPHiA DDM™ for the Agilent SureSelect
Cancer CGP application, Dhiti Omics will improve its ability to
provide researchers actionable information on mutations and
biomarkers across hundreds of genes.
"Our team at Dhiti Omics is passionate about furthering the use
of precision medicine and ensuring people in India and throughout the world have access to
testing for better health outcomes," said Sudha N. Rao, Ph.D., Founder and Director of
Dhiti Omics Technologies. "Combining high-quality reagents, and
powerful analytics into one unique workflow will help us maximize
insights from comprehensive genomic profiling data. This will
ensure we're delivering the fastest and most accurate diagnostics
to our customer base."
SOPHiA DDM™ for SureSelect CGP application combines
Agilent's best-in-class genomic profiling assay kit with the SOPHiA
DDM™ Platform. Launched in 2023, SureSelect Cancer CGP application
offers comprehensive genomic profiling. With the SOPHiA DDM™ AI
Platform, Dhiti Omics will have an integrated solution for rapid
and accurate insights on the basis of the latest guidelines
reflecting relevant biomarkers.
"Our Platform and applications are designed to enable companies
like Dhiti Omics to more easily advance precision medicine," said
Ricardo Mendonca Filho, Ph.D.,
Managing Director, LAPAC, SOPHiA GENETICS. "By using SOPHiA
DDM™, Dhiti Omics can ensure speed and accuracy of solid tumor
testing to best support the Indian population."
The combined efforts of Agilent and SOPHiA GENETICS make it
possible for companies like Dhiti Omics to facilitate novel
approaches to cancer research and diagnostics.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator of
the SOPHiA DDM™ Platform, which analyzes complex genomic and
multimodal data and generates real-time, actionable insights for a
broad global network of hospital, laboratory, and biopharma
institutions. For more information, visit SOPHiAGENETICS.COM
and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/india-based-dhiti-omics-is-now-live-on-sophia-ddm-302189403.html
SOURCE SOPHiA GENETICS